Fonseca V, Mikhailidis D P, Barradas M A, Jeremy J Y, Gracey L, Dandona P
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital and School of Medicine, London, England.
Int J Clin Pharmacol Res. 1988;8(5):377-81.
In a double-blind placebo-controlled trial, buflomedil was shown to cause a significant increase both in median claudication provoking time from 63 sec (range: 24-136 sec) to 124 sec (range: 53-261 sec) (p less than 0.01), and in maximum walking distance (MWD) from 169m (range: 157-308 m) to 293 m (range: 107-429 m) (p less than 0.01). The MWD after three months' buflomedil treatment was also significantly (p = 0.05) prolonged when compared with the MWD in the appropriate placebo group. In contrast, treatment with the placebo caused no significant change in these indices. Subjective improvement was observed in 12 out of 14 patients on buflomedil, whilst it occurred in only 6 out of 14 patients on the placebo (p less than 0.05). The clinical improvement was not associated with an increase in the ankle pressure index or a reduction in platelet aggregation and thromboxane A2 release.
在一项双盲安慰剂对照试验中，已表明丁咯地尔可使间歇性跛行激发时间中位数从63秒（范围：24 - 136秒）显著增加至124秒（范围：53 - 261秒）（p < 0.01），并使最大步行距离（MWD）从169米（范围：157 - 308米）增加至293米（范围：107 - 429米）（p < 0.01）。与相应安慰剂组的MWD相比，丁咯地尔治疗三个月后的MWD也显著延长（p = 0.05）。相比之下，安慰剂治疗对这些指标无显著影响。在接受丁咯地尔治疗的14名患者中，有12名观察到主观改善，而接受安慰剂治疗的14名患者中只有6名出现主观改善（p < 0.05）。临床改善与踝压指数增加或血小板聚集及血栓素A2释放减少无关。
